Actionable biomarker-informed treatment decisions rely on the acquisition of quality tissue samples1-4   Sufficient amounts of quality tumor specimens enable identification of actionable determination of biomarkers5 Careful, proactive management of tissue is critical in order to maximize its availability for downstream testing5 Testing at initial diagnosis can help optimize the use of precious tissue and […]

In case of tissue insufficiency, ctDNA acquired through liquid biopsy can be tested7,8   ctDNA is obtained through minimally invasive methods to study biomarkers in body fluids (eg, blood)9,10 ctDNA testing can be used to detect genomic alterations that can be linked to targeted therapy options11